National Research Corp (NASDAQ: NRC) has gained $0.89 (2.70%) and sits at $33.65, as of 11:53:48 est on May 13.

9,476 shares have traded hands.

The Company has risen 3.26% over the last 5 days and shares have fallen 17.27% over the last 30 days.

National Research anticipates its next earnings on 2022-08-02.

For technical charts, analysis, and more on National Research visit the company profile.

About National Research Corp

NRC Health is the leading provider of in-depth customer insights in healthcare.

To get more information on National Research Corp and to follow the company's latest updates, you can visit the company's profile page here: National Research Corp's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast

Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement

Target Hits 52-Week Low After Missing Badly on First Quarter Earnings

DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter

Another Crypto Winter Wipes Out Billions in Market Value

Inflation + Recession = Recipe for Volatility

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold

The Best Laid Plans of Mice and Men — Part I